Back to Screener

Healthcare

Abiomed, Inc.(ABMD)

Data coverage status ยท 6 need attention

Quote: Stale

Quote synced 2026-08-02T22:23:27.929802Z

Daily bars through 2022-12-23 ยท Stale

Daily bars synced 2026-07-03T20:20:20.212035Z

Fundamentals through 2026-05-04 ยท Delayed

Fundamentals synced 2026-05-18T20:32:47.306219Z

Forecasts: Missing

Forecasts synced 0001-01-01T00:00:00Z

Ownership: Missing

Ownership synced 2026-05-18T20:32:47.306219Z

Short interest: Missing

Short interest synced 2026-05-18T20:32:47.306219Z

News: Missing

News synced 0001-01-01T00:00:00Z

Company profile: Delayed

Company profile synced 2026-05-06T21:57:33.1761Z

Regular-session price

Offline

โ€”

1Y Change

โ€”

Window

No data

Market Cap
$17.18B
P/E
126.8
Trailing
52W Range
$219.85 - $381.99
Volume
15.70M
7.2x RVOL

Investment Snapshot

Valuation, growth, profitability, catalysts, and benchmark context.

Quote + TTM fundamentalsForecast

1D

โ€”

1M

โ€”

6M

โ€”

YTD

โ€”

1Y

โ€”

No coverage

Historical coverage is still loading

We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.

No price data

Benchmark Edge

ABMD vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

ABMD

โ€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

ABMD Max Drawdown

โ€”

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for ABMD and SPY.

Calendar-year return history is still loading or unavailable.

Financials

Abiomed, Inc. financial statements

Annual, quarterly, and TTM views with reported currency, units, source, download, and filing context.

Period

Units

Reported currency

USD

Source

Provider

Last checked

--

View: AnnualUnits: USD millionsLatest period: --

Latest Revenue

--

Latest Net Income

--

Free Cash Flow

--

Revenue Growth

+21.7%

EPS Growth

-40.0%

Gross Margin

81.8%

Net Margin

13.2%

No financial statement data available for ABMD in annual view.

Next Step

Turn financials into a decision

Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.